Treating Rare MPN Diseases Caused by Genetic Mutations in Blood Stem Cells with Dr. Hugh Rienhoff Imago BioSciences TRANSCRIPT
Download PDFSep 12, 2021
Dr. Hugh Rienhoff is the Founder and Chief Executive Officer at Imago BioSciences. He and his team are developing their lead asset bomedemstat for the treatment of myeloproliferative neoplasms (MPNs) which are rare blood cancers.
Hugh explains, "So MPNs, myeloproliferative neoplasms, are actually a family of diseases...
Sep 12, 2021
Dr. Hugh Rienhoff is the Founder and Chief Executive Officer at Imago BioSciences. He and his team are developing their lead asset bomedemstat for the treatment of myeloproliferative neoplasms (MPNs) which are rare blood cancers.
Hugh explains, "So MPNs, myeloproliferative neoplasms, are actually a family of diseases...
Accelerating Development of Treatments for Spinal Muscular Atrophy with Karen Chen SMA Foundation TRANSCRIPT
Download PDFAug 30, 2021
Karen Chen is the Chief Executive Officer of the Spinal Muscular Atrophy Foundation. With a background in drug development having worked in pharma and biotech in neurodegenerative diseases like Alzheimer's and Parkinson's, Karen brings a deep understanding of the value of treating rare diseases that are genetically...
Aug 30, 2021
Karen Chen is the Chief Executive Officer of the Spinal Muscular Atrophy Foundation. With a background in drug development having worked in pharma and biotech in neurodegenerative diseases like Alzheimer's and Parkinson's, Karen brings a deep understanding of the value of treating rare diseases that are genetically...
Promise of New Treatments for Spinal Muscular Atrophy with Dan Temple SMA Patient Advocate TRANSCRIPT
Download PDFAug 23, 2021
Dan Temple is a patient advocate for those with Spinal Muscular Atrophy (SMA) and he shares his treatment journey and actions he has taken to raise awareness about SMA. We also talk about the drug treatments that have come onto the scene since he was first diagnosed when Dan was 2 years old. He is now 49.
Dan says,...